Cargando…

Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis

BACKGROUND: Ovarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequen...

Descripción completa

Detalles Bibliográficos
Autores principales: Maleki, Zahra, Vali, Mohebat, Nikbakht, Hossein-Ali, Hassanipour, Soheil, Kouhi, Aida, Sedighi, Saman, Farokhi, Roya, Ghaem, Haleh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276364/
https://www.ncbi.nlm.nih.gov/pubmed/37328812
http://dx.doi.org/10.1186/s12885-023-11041-8
_version_ 1785060060454453248
author Maleki, Zahra
Vali, Mohebat
Nikbakht, Hossein-Ali
Hassanipour, Soheil
Kouhi, Aida
Sedighi, Saman
Farokhi, Roya
Ghaem, Haleh
author_facet Maleki, Zahra
Vali, Mohebat
Nikbakht, Hossein-Ali
Hassanipour, Soheil
Kouhi, Aida
Sedighi, Saman
Farokhi, Roya
Ghaem, Haleh
author_sort Maleki, Zahra
collection PubMed
description BACKGROUND: Ovarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequently leads to late diagnosis. Survival rate of patients diagnosed with ovarian cancer can be used in order to better assess current standard of care; the aim of this study is to evaluate the survival rate of ovarian cancer patients in Asia. METHODS: Systematic review was performed on articles that were published by the end of August 2021 in five international databases, including Medline / PubMed, ProQuest, Scopus, Web of Knowledge, and Google Scholar. The Newcastle-Ottawa quality evaluation form was used for cohort studies to evaluate the quality of the articles. The Cochran-Q and I(2) tests were used to calculate the heterogeneity of the studies. The Meta-regression analysis was also done according to when the study was published. RESULTS: A total of 667 articles were reviewed, from which 108 were included in this study because they passed the criteria. Based on a randomized model, the survival rates of ovarian cancer after 1, 3 and 5 years were respectively 73.65% (95% CI, 68.66–78.64), 61.31% (95% CI, 55.39–67.23) and 59.60% (95% CI, 56.06–63.13). Additionally, based on meta-regression analysis, there was no relationship between the year of study and survival rate. CONCLUSIONS: The 1-year survival rate was higher than that of 3- and 5-year for ovarian cancer. This study provides invaluable information that can not only help establish better standard of care for treatment of ovarian cancer, but also assist in development of superior health interventions for prevention and treatment of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11041-8.
format Online
Article
Text
id pubmed-10276364
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-102763642023-06-18 Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis Maleki, Zahra Vali, Mohebat Nikbakht, Hossein-Ali Hassanipour, Soheil Kouhi, Aida Sedighi, Saman Farokhi, Roya Ghaem, Haleh BMC Cancer Research BACKGROUND: Ovarian cancer is amongst one of the most commonly occurring cancers affecting women, and the leading cause of gynecologic related cancer death. Its poor prognosis and high mortality rates can be attributed to the absence of specific signs and symptoms until advance stages, which frequently leads to late diagnosis. Survival rate of patients diagnosed with ovarian cancer can be used in order to better assess current standard of care; the aim of this study is to evaluate the survival rate of ovarian cancer patients in Asia. METHODS: Systematic review was performed on articles that were published by the end of August 2021 in five international databases, including Medline / PubMed, ProQuest, Scopus, Web of Knowledge, and Google Scholar. The Newcastle-Ottawa quality evaluation form was used for cohort studies to evaluate the quality of the articles. The Cochran-Q and I(2) tests were used to calculate the heterogeneity of the studies. The Meta-regression analysis was also done according to when the study was published. RESULTS: A total of 667 articles were reviewed, from which 108 were included in this study because they passed the criteria. Based on a randomized model, the survival rates of ovarian cancer after 1, 3 and 5 years were respectively 73.65% (95% CI, 68.66–78.64), 61.31% (95% CI, 55.39–67.23) and 59.60% (95% CI, 56.06–63.13). Additionally, based on meta-regression analysis, there was no relationship between the year of study and survival rate. CONCLUSIONS: The 1-year survival rate was higher than that of 3- and 5-year for ovarian cancer. This study provides invaluable information that can not only help establish better standard of care for treatment of ovarian cancer, but also assist in development of superior health interventions for prevention and treatment of the disease. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12885-023-11041-8. BioMed Central 2023-06-16 /pmc/articles/PMC10276364/ /pubmed/37328812 http://dx.doi.org/10.1186/s12885-023-11041-8 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Maleki, Zahra
Vali, Mohebat
Nikbakht, Hossein-Ali
Hassanipour, Soheil
Kouhi, Aida
Sedighi, Saman
Farokhi, Roya
Ghaem, Haleh
Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis
title Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis
title_full Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis
title_fullStr Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis
title_full_unstemmed Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis
title_short Survival rate of ovarian cancer in Asian countries: a systematic review and meta-analysis
title_sort survival rate of ovarian cancer in asian countries: a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10276364/
https://www.ncbi.nlm.nih.gov/pubmed/37328812
http://dx.doi.org/10.1186/s12885-023-11041-8
work_keys_str_mv AT malekizahra survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis
AT valimohebat survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis
AT nikbakhthosseinali survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis
AT hassanipoursoheil survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis
AT kouhiaida survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis
AT sedighisaman survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis
AT farokhiroya survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis
AT ghaemhaleh survivalrateofovariancancerinasiancountriesasystematicreviewandmetaanalysis